
People with type 2 diabetes face heightened risks for heart attack and stroke, as well as progressive kidney disease. But a new once-a-week injected drug called efpeglenatide could greatly reduce their odds for those outcomes, new research shows. The clinical trial was conducted in over 28 nations and involved more than 4,000 patients with type… read on > read on >